Literature DB >> 8434447

Conservative treatment of jimsonweed ingestion.

G C Rodgers1, R L Von Kanel.   

Abstract

The use of physostigmine for the treatment of jimsonweed ingestion remains controversial. We have reviewed the records of 29 cases reported to the Kentucky Regional Poison Center (KRPC) over a 7-y period during which time physostigmine was not recommended by the Center to assess the results of conservative therapy. 28/29 cases represented intentional abuse; 26/29 were males and the mean age for the group was 18.9 y (range 16 mo to 39 y). The reported ingested amounts ranged from a few to 1/2-cup of seeds. Typical mild anticholinergic symptoms including mydriasis, tachycardia, flushing, hallucinations, and both agitated behavior and lethargy were observed. No patient had life-threatening symptoms. All cases were referred to the Emergency Department, although only 20 complied. Of these, 17 were admitted for stays of 1-3 d (mean 1.8). Seventeen patients received activated charcoal on recommendation of the KRPC. Three patients with hallucinations received 1 or more doses of valium or haloperidol for sedation. All patients recovered uneventfully. We conclude that conservative treatment of jimsonweed ingestion is safe and adequate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8434447

Source DB:  PubMed          Journal:  Vet Hum Toxicol        ISSN: 0145-6296


  3 in total

1.  Acute poisoning due to ingestion of Datura stramonium - a case report.

Authors:  Sebastian Daniel Trancă; Robert Szabo; Mihaela Cociş
Journal:  Rom J Anaesth Intensive Care       Date:  2017-04

2.  Timing and frequency of physostigmine redosing for antimuscarinic toxicity.

Authors:  Christopher Rosenbaum; Steven B Bird
Journal:  J Med Toxicol       Date:  2010-12

3.  Datura stramonium L. poisoning in a geophagous child: a case report.

Authors:  Asma Bouziri; Asma Hamdi; Aida Borgi; Sarra Bel Hadj; Zohra Fitouri; Khaled Menif; Nejla Ben Jaballah
Journal:  Int J Emerg Med       Date:  2011-06-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.